Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Advanced Solid Tumor 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × famitinib × 1 year × Clear all
NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
48 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

NCT05208177 2025-08-22

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
25 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
194 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡